Fluid retention and heart failure in the PRECISION trial

Affiliations

¹ Division of Nephrology,University of Utah Health, Salt Lake City, UT 84132, USA. Electronic address: donald.kohan@hsc.utah.edu.
² Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, Netherlands.

Comment

Donald E Kohan et al. Lancet. 2023.

. 2023 Apr 22;401(10385):1335.

doi: 10.1016/S0140-6736(23)00275-1.

¹ Division of Nephrology,University of Utah Health, Salt Lake City, UT 84132, USA. Electronic address: donald.kohan@hsc.utah.edu.
² Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, Netherlands.

No abstract available

Comment in

Fluid retention and heart failure in the PRECISION trial - Authors' reply.
Schlaich MP, Bellet M, Weber MA, Bakris GL, Wang JG; PRECISION investigators. Schlaich MP, et al. Lancet. 2023 Apr 22;401(10385):1335-1336. doi: 10.1016/S0140-6736(23)00272-6. Lancet. 2023. PMID: 37087163 No abstract available.

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG; PRECISION investigators. Schlaich MP, et al. Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. Epub 2022 Nov 7. Lancet. 2022. PMID: 36356632 Clinical Trial.